Apoha

What Apoha does

Apoha is a London- and San Francisco-based deep technology company founded in 2021 that emerged from stealth mode in June 2026 with $36 million in cumulative funding. The company develops and commercialises Liquid State Intelligence (LSI), a proprietary measurement platform that captures how molecules, formulations, and materials behave under real-world stresses by introducing tiny samples onto engineered liquid interfaces held near thermodynamic transitions and reading the resulting time-domain wave patterns. Its core measurement output, VIBE (Variations in Interfacial Behaviour under Excitation), produces high-dimensional behavioural fingerprints from as little as 8-10 micrograms of material, positioning behavioural data as a third data class alongside sequence and structure data for molecular science.

Commercially, Apoha operates a tiered partnership model: program pilots at roughly £100 per sample for proof-of-value, program partnerships delivering standardised behavioural embeddings for customers' internal machine-learning use, and multi-year strategic data partnerships providing proprietary compounding data layers. The current delivery model is centralised service (customers ship samples to Apoha's labs), with on-site instrument deployment into partner laboratories announced as the next step. Go-to-market is enterprise field sales led by scientific credibility, anchored by multi-year research collaborations with Boehringer Ingelheim (>90% precision in identifying high-risk antibody candidates from 71 clinical-stage antibodies with zero false positives), Mythic Therapeutics (86% precision in VHH-Fc developability ranking), Somru Bioscience (real-time bioprocess monitoring across 14-day production cycles), and Dandelion Diagnostics (serum sample characterisation for disease diagnosis). Primary revenue verticals are pharmaceutical and biotechnology R&D, with adjacent expansion into food and beverage sensory intelligence, clinical diagnostics, and academic research collaborations with Johns Hopkins, Oxford, Stevens Institute, and the University of Leeds.

Name

Apoha

Legal name

Apoha Inc.

Website

https://apoha.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Apoha develops and commercialises Liquid State Intelligence, a proprietary measurement platform that captures molecular behaviour from engineered liquid interfaces. It serves R&D teams in pharmaceutical, biotech, food & beverage, and diagnostics industries through tiered partnerships and per-sample service engagements.

Ownership category

akta.pro rank

Product category

Molecular Behavior Analytics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Analytical Laboratory Instrument Manufacturing (334516)

SIC

Services-Commercial Physical & Biological Research (8731), Laboratory Analytical Instruments (3826), Services-Testing Laboratories (8734)

akta.pro primary industry

Method Development & Validation (ICH/USP) (HLAGADAB)

Keywords

• Molecular behavior measurement
• Antibody developability screening
• Biophysical characterization services
• Sensory intelligence analysis
• Protein formulation analytics

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Service-based measurement programs: Per-sample pricing model where customers pay for measurement services. Pilots typically land in range of ~£100/sample with more favourable terms when customer data can contribute to model training. Engagement typically starts with a program pilot (defined set of molecules measured and benchmarked), progresses to program partnerships (standardized behavioural embeddings for internal ML use), and can expand to strategic data partnerships (proprietary behavioural data layers that compound with every measurement).
2. Strategic Data Partnerships: Long-term partnerships providing proprietary behavioural data layers that compound with every measurement, building advantages competitors cannot replicate. These include standardized behavioural embeddings and datasets designed for internal ML use, with compatibility with existing sequence and structure models.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Core offering

Apoha provides a proprietary Liquid State Intelligence measurement service that captures how molecules, formulations, and materials behave under real-world stresses. Customers send samples (typically tens to hundreds per pilot) to Apoha's centralized labs where the samples are deposited onto engineered liquid interfaces near thermodynamic transitions; time-domain wave emissions are read as dynamic signatures and converted into high-dimensional behavioral fingerprints called VIBE (Variations in Interfacial Behaviour under Excitation). Delivered primarily as a per-sample measurement service to enterprise pharmaceutical, biotech, and food & beverage R&D teams, with structured tiered engagements progressing from proof-of-value pilots to multi-year strategic data partnerships.

Product overview

Apoha offers Liquid State Intelligence™ as its core technology platform, which uses a novel measurement approach to capture molecular behavior data that traditional characterization methods cannot access. The platform is delivered primarily as a service, with customers sending samples for analysis. The product suite includes VIBE™ (Variations in Interfacial Behaviour under Excitation) as the primary measurement output, with specialized service offerings for Pharma & Biotech (antibody developability, bioprocess monitoring, formulation optimization) and Food & Beverage (sensory intelligence, reformulation, competitor analysis) industries. Partnerships are offered at three levels: program pilots, program partnerships with ML integration, and strategic data partnerships.

Differentiator

Problem solved

Functional benefit

Products and services

• Pharma & Biotech Measurement Services Industry-specific measurement services for therapeutic antibody and biologic developers. Includes VIBE developability checks at hit-identification and lead selection, comprehensive developability profiling (aggregation, hydrophobicity, stability), formulation condition testing across pH, concentration, and buffer variations, and real-time bioprocess monitoring across 14-day production cycles. Validated with over 90% precision in high-risk antibody identification (Boehringer Ingelheim), 86% precision in VHH-Fc ranking (Mythic Therapeutics), and 3-phase production monitoring (Somru Bioscience).
• Food & Beverage Measurement Services Sensory intelligence measurement services for food and beverage formulation teams. Includes sweetener replacement analysis, plant-protein interchangeability assessment, competitor product mapping, and prototype screening based on physicochemical measurements that predict consumer panel outcomes. Case study examples include sweetener selection across 8 candidates in 2 weeks for a major UK beverage company, and identification of viable plant-protein substitutes from 15 candidates in days for a UK alternative food protein company.
• Tiered Partnership Engagement Programs Three-tier structured engagement offering: Program Pilot (proof of value on a defined set of molecules measured and benchmarked against customer's internal controls, typically tens to hundreds of samples), Program Partnership (standardized behavioural embeddings for internal ML use compatible with existing sequence and structure models, under multi-year contracts), and Strategic Data Partnership (proprietary behavioural data layers that compound with every measurement, with custom pricing and ongoing collaboration requirements).

Quantifiable outcome

• Greater than 90% precision in identifying high-risk antibody candidates
• +6 more outcomes

Named customers8 records

Segments3 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Boehringer IngelheimcoreStrategic or Co-development Partner · 9 May 2025Multi-year research collaboration validating Liquid State Intelligence platform for antibody developability screening. Joint publication on bioRxiv demonstrating >90% precision in identifying high-risk antibody candidates from 71 clinical-stage antibodies with zero false positives. Also collaborated on real-time bioprocess monitoring demonstrating 3-phase production trajectory detection across 14-day cycles.
• Mythic TherapeuticscoreStrategic or Co-development Partner · 1 January 2025Clinical-stage biotechnology company developing antibody-drug conjugates (ADCs). Collaboration validated VIBE for developability risk ranking in proprietary VHH-Fc panel. Screening of 71 proprietary VHH-Fc candidates demonstrated 86% precision against HIC benchmarks. Company integrating Liquid State Intelligence at start of next program for hit identification insights.
• Somru BiosciencecoreStrategic or Co-development Partner · 1 January 2024Canadian biopharmaceutical CDMO specializing in biosimilar development. Jointly funded project to develop high-resolution Process Analytical Technology (PAT) framework. Collaboration demonstrated real-time antibody biophysical monitoring across 14-day production cycles with daily sampling capability. Study tracked 4 antibody batches showing reproducible 3-phase maturation trajectories.
• EthrisminorStrategic or Co-development PartnerBiotechnology partner listed on partnerships page. Ethris develops mRNA therapeutics.
• Dandelion DiagnosticsminorStrategic or Co-development PartnerDiagnostics partner. Apoha unlocked characterization space for clinically relevant serum samples, providing signals to boost predictive power of models for disease diagnosis.
• Johns Hopkins UniversityminorStrategic or Co-development PartnerAcademic partnership for collaborative research pushing the field of molecular behaviour characterization forward.
• University of OxfordminorStrategic or Co-development PartnerAcademic partnership. CEO Shamit Shrivastava conducted postdoctoral research at Oxford's Institute for Biomedical Engineering. Ongoing collaboration in biophysics and interfacial science.
• Stevens Institute of TechnologyminorStrategic or Co-development PartnerAcademic partnership for collaborative research in molecular science and characterization technologies.
• University of LeedsminorStrategic or Co-development PartnerAcademic partnership for collaborative research advancing molecular behaviour science.

Scale indicators4 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• Unchained Labs: Direct peer offering biologics stability, formulation, and developability instruments (e.g., Uncle, Hunky, Panta). Competes in the same biologics characterization space Apoha targets with antibody developability and formulation workflows.
• Carterra: Direct peer providing high-throughput label-free antibody kinetics and epitope characterization via SPR (LSA platform). Competes for the same antibody discovery and developability budget Apoha targets in pharma/biotech R&D.
• Wyatt Technology: Direct peer in biophysical characterization with light scattering and SEC-MALS instruments used for protein aggregation, stability, and developability assessment. Competes in the same biologics characterization toolkit that Apoha's VIBE aims to complement or displace.

Emerging players

• 908 Devices: Emerging player bringing novel mass-spec and microfluidic analytical tools to bioprocess monitoring and molecular characterization. Closely aligned with Apoha's bioprocess and PAT use cases (Somru partnership) and targets similar pharma process development customers.
• AbCellera Biologics: Emerging player in antibody discovery with computational and high-throughput wet-lab capabilities. Overlaps with Apoha's antibody developability screening opportunity as a customer-side partner rather than direct technology competitor.

Broad incumbents

• Cytiva: Broad incumbent (formerly GE Healthcare Life Sciences) supplying bioprocess and analytical instruments across pharma R&D and manufacturing. Competes with Apoha for the same pharma characterization and PAT budgets, though as part of a much larger portfolio.
• Sartorius: Broad incumbent in bioprocess and lab analytics including the FortéBio BLI platform for label-free protein interaction analysis. Targets the same antibody developability and bioprocess monitoring customers with an established installed base.
• Bio-Rad Laboratories: Broad incumbent in protein analytical instruments including NGC chromatography, Bio-Plex, and surface plasmon resonance systems used in biologics characterization and quality control. Competes for the same pharma/biotech analytical instrumentation budget.
• Thermo Fisher Scientific: Broad incumbent with extensive analytical instrument, bioprocess, and CRO offerings including mass spectrometry, chromatography, and protein characterization systems. Could rapidly enter Apoha's niche either organically or via acquisition.

Others

• Eurofins Scientific: Large contract testing services network with capabilities in pharma, food, and environmental analytical services. Adjacent rather than directly competing — Eurofins could be a partner, acquirer, or competitive threat for Apoha's centralized service model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/apoha

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds9 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Apoha